Aarti Pharmalabs Ltd informed the stock exchanges that it has received an ex-parte ad-interim injunction from the Hon’ble High Court of Delhi restraining the company from manufacturing, stockpiling, exporting, offering for sale, or supplying, directly or indirectly, any pharmaceutical products containing the compound Ruxolitinib or Ruxolitinib Phosphate API, as well as any other formulation that may infringe Patent No. IN269841.

Following the order, a Local Commissioner and their team visited the company’s office premises to inspect records and took copies of ledgers, stock registers, and other relevant documents. The company fully cooperated with the authorities and provided all requested clarifications.

The company clarified that its business operations continue as usual and were not impacted by the inspection or the order.

The injunction arises from an alleged patent infringement related to heteroaryl substituted Pyrrolo[2,3-b] Pyridines and Pyrrolo[2,3-b] Pyrimidines as Janus Kinase Inhibitors. The company stated that there is no financial impact on its operations as a result of the order.